Albemarle (NYSE:ALB) Stock Price Target Raised at CICC Research

Albemarle (NYSE:ALB – Free Report) had its target price lifted by CICC Research from $83.28 to $108.58 in a research note issued to investors on Wednesday.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings upgraded shares of Albemarle from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. Bank of America cut their price target on Albemarle from $155.00 to $131.00 and set a “buy” rating on the stock in a research report on Monday, October 19th. Argus cut their price target on Albemarle from $230.00 to $135.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. JPMorgan Chase & Co. reduced their price objective on Albemarle from $160.00 to $140.00 and set a “neutral” rating for the company in a research note on Tuesday, August 25th. Finally, Citigroup boosted their price objective on Albemarle from $125.00 to $140.00 and gave the company a “buy” rating in a report on Monday. Fifteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $152.63.

View Our Latest Research Report on ALB

Albemarle Stock Performance

NYSE:ALB traded down $1.23 during midday trading on Wednesday, hitting $93.62. The company’s stock had a trading volume of 706,251 shares, compared to its average volume of 2,457,464. Albemarle has a fifty-two week low of $89.77 and a fifty-two week high of $221.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.34 and a quick ratio of 1.57. The firm has a market cap of $11.05 billion, a P/E ratio of 22.61, a P/E/G ratio of 0.60 and a beta of 1.34. The firm’s 50 day moving average is $104.38 and its 200-day moving average is $146.06.

Albemarle (NYSE:ALB – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Albemarle had a net margin of 10.40% and a return on equity of 14.91%. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.19) EPS. Equities analysts anticipate that Albemarle will post 10.70 earnings per share for the current fiscal year.

Albemarle Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, December 18th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Friday, December 18th. Albemarle’s payout ratio is 39.61%.

Institutional Investors Weigh In On Albemarle

Several hedge funds have recently modified their holdings of ALB. State Board of Administration of Florida Retirement System grew its position in shares of Albemarle by 348.3% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 440,083 shares of the specialty chemicals company’s stock valued at $46,552,000 after acquiring an additional 341,926 shares during the period. Essex Financial Services Inc. purchased a new position in shares of Albemarle in the 3rd quarter valued at about $1,096,000. Ingalls & Snyder LLC increased its stake in shares of Albemarle by 52.5% in the 3rd quarter. Ingalls & Snyder LLC now owns 3,031 shares of the specialty chemicals company’s stock valued at $321,000 after purchasing an additional 1,043 shares in the last quarter. AlphaGrep UK Ltd increased its stake in shares of Albemarle by 133.0% in the 3rd quarter. AlphaGrep UK Ltd now owns 4,431 shares of the specialty chemicals company’s stock valued at $469,000 after purchasing an additional 2,529 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its holdings in Albemarle by 212.3% in the 3rd quarter. Benjamin Edwards Inc. now owns 17,422 shares of the specialty chemicals company’s stock worth $1,843,000 after purchasing an additional 11,843 shares during the period. 92.87% of the stock is owned by hedge funds and other institutional investors.

Albemarle Company Profile

(Get Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

See Also

Analyst Recommendations for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.